Search research articles
Contact Us
Filters
Showing results (31-40 of 48) with videos related to
Page
of 5
Sort By:
JAMA
|
August 9, 2018
Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non-Small Cell Lung Cancer in the Community Oncology Setting
Carolyn J Presley, Daiwei Tang, Pamela R Soulos, et al.
Contemporary Clinical Trials Communications
|
March 3, 2025
Real-world enrollment for a prospective clinico-genomic database using a pragmatic technology-enabled platform
Alexia Exarchos, Ariel B Bourla, Maneet Kaur, et al.
JCO Oncology Practice
|
January 20, 2023
Associations of Early Completion of Advance Directives With Key End-of-Life Quality Measures: Analysis of an ASCO Quality Oncology Practice Initiative Patient Cohort
Steve Power, Kathleen Bickel, Ronald C Chen, et al.
JAMA Oncology
|
May 26, 2018
Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials
Jeremy M O'Connor, Kristen L Fessele, Jean Steiner, et al.
Clinical Lung Cancer
|
April 22, 2026
Consolidative Radiotherapy for Extensive-Stage Small Cell Lung Cancer: Outcomes Based on Completeness of Consolidation and Oligometastatic State
James G Ninia, Nipun Verma, Jessica B Long, et al.
JTO Clinical and Research Reports
|
August 1, 2025
Real-World Validity of Tissue-Agnostic Circulating Tumor DNA Response Monitoring in Lung Cancers Treated With Chemotherapy, Immunotherapy, or Targeted Agents
Anne C Chiang, Russell W Madison, Zoe June Assaf, et al.
Journal of Oncology Practice
|
December 12, 2018
Measuring the Impact of Academic Cancer Network Development on Clinical Integration, Quality of Care, and Patient Satisfaction
Anne C Chiang, Jessica Lake, Naralys Sinanis, et al.
The Lancet. Oncology
|
June 9, 2016
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial
Sarah B Goldberg, Scott N Gettinger, Amit Mahajan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 24, 2026
Corrigendum to 'Patient-Reported Outcomes With Consolidation Durvalumab Versus Placebo After Concurrent Chemoradiotherapy in Limited-Stage SCLC: Results From the Phase 3 ADRIATIC Trial' [Journal of Thoracic Oncology volume 21 issue 6 (2026) 103564]
Silvia Novello, David R Spigel, Jian Fang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 1, 2026
Patient-Reported Outcomes with Consolidation Durvalumab Versus Placebo Following Concurrent Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer: Results from the Phase 3 ADRIATIC Trial
Silvia Novello, Ying Cheng, David Spigel, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 48) with videos related to
Sort By:
Page
of 5
JAMA
|
August 9, 2018
Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non-Small Cell Lung Cancer in the Community Oncology Setting
Carolyn J Presley, Daiwei Tang, Pamela R Soulos, et al.
Contemporary Clinical Trials Communications
|
March 3, 2025
Real-world enrollment for a prospective clinico-genomic database using a pragmatic technology-enabled platform
Alexia Exarchos, Ariel B Bourla, Maneet Kaur, et al.
JCO Oncology Practice
|
January 20, 2023
Associations of Early Completion of Advance Directives With Key End-of-Life Quality Measures: Analysis of an ASCO Quality Oncology Practice Initiative Patient Cohort
Steve Power, Kathleen Bickel, Ronald C Chen, et al.
JAMA Oncology
|
May 26, 2018
Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials
Jeremy M O'Connor, Kristen L Fessele, Jean Steiner, et al.
Clinical Lung Cancer
|
April 22, 2026
Consolidative Radiotherapy for Extensive-Stage Small Cell Lung Cancer: Outcomes Based on Completeness of Consolidation and Oligometastatic State
James G Ninia, Nipun Verma, Jessica B Long, et al.
JTO Clinical and Research Reports
|
August 1, 2025
Real-World Validity of Tissue-Agnostic Circulating Tumor DNA Response Monitoring in Lung Cancers Treated With Chemotherapy, Immunotherapy, or Targeted Agents
Anne C Chiang, Russell W Madison, Zoe June Assaf, et al.
Journal of Oncology Practice
|
December 12, 2018
Measuring the Impact of Academic Cancer Network Development on Clinical Integration, Quality of Care, and Patient Satisfaction
Anne C Chiang, Jessica Lake, Naralys Sinanis, et al.
The Lancet. Oncology
|
June 9, 2016
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial
Sarah B Goldberg, Scott N Gettinger, Amit Mahajan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 24, 2026
Corrigendum to 'Patient-Reported Outcomes With Consolidation Durvalumab Versus Placebo After Concurrent Chemoradiotherapy in Limited-Stage SCLC: Results From the Phase 3 ADRIATIC Trial' [Journal of Thoracic Oncology volume 21 issue 6 (2026) 103564]
Silvia Novello, David R Spigel, Jian Fang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 1, 2026
Patient-Reported Outcomes with Consolidation Durvalumab Versus Placebo Following Concurrent Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer: Results from the Phase 3 ADRIATIC Trial
Silvia Novello, Ying Cheng, David Spigel, et al.
Page
of 5